Lallemand Consolidates Enzyme Operations under Solyve for Enhanced F&B Supply
Lallemand has launched Solyve as a dedicated food and beverage enzyme business, aiming to streamline customer engagement and capitalise on recent acquisitions. This consolidation enhances enzyme supply chain resilience and fosters innovation in processing efficiency.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Lallemand has formally established Solyve as its dedicated food and beverage enzyme business, integrating scientific, manufacturing, and customer support functions under one umbrella. This strategic move aims to present a unified market interface for enzyme solutions, building on Lallemand's recent acquisition-led expansion. While existing product brands and supply commitments remain unchanged, the consolidation seeks to enhance operational efficiency and market presence, according to Lars Asferg, President and General Manager of Lallemand Bio-Ingredients.
The creation of Solyve follows Lallemand's recent acquisition of Bio-Cat Enzymes & Microbials, which expanded its US manufacturing capabilities across enzymes, probiotics, and microbials. This strengthens Lallemand's production footprint, crucial for meeting increasing demand for resilient enzyme supplies and mitigating raw material price volatility. The company's enzyme expression technology leverages both yeast-based methods and fungal solid-state fermentation, underpinning its development, formulation, quality assurance, and regulatory expertise.
This market development occurs amidst broader industry investment in enzyme capabilities. Novonesis, a competitor, is investing €600 million (approximately £510 million) in a new Indian enzyme production facility expected to be operational by 2030. This investment reflects a sector-wide drive towards improved supply reliability and shorter lead times for customers in high-growth markets like India, the Middle East, and Africa.
Enzyme innovation continues to focus on enhancing processing efficiency and product performance. Examples include Curie Co.'s Curabind, an enzyme that stabilises proteins, boosting cheese curd yields by up to 11% and strained yogurt mass by 25%, while potentially extending shelf life and reducing reliance on gums. Kerry's Acrylerase amidase enzyme, approved by the European Food Safety Authority (EFSA), demonstrates targeted solutions by reducing acrylamide levels in coffee extracts by up to 90% without compromising taste or requiring workflow changes. Similarly, IFF's Diazyme Nolo transglucosidase enzyme supports 'no/low' alcohol beer production by reducing grist use, offering brewers an economical base for craft-style profiles.
What this means for United Kingdom
UK supplement manufacturers and brand owners will experience enhanced access to advanced enzyme technologies for product reformulation and supply chain optimisation. The consolidation under Solyve could lead to more stable enzyme pricing and improved lead times for specific ingredients, benefiting production planning. Manufacturers developing protein-rich or 'clean label' products can leverage enzymes for yield improvements of up to 25% or to reduce costly hydrocolloid use. Regulatory teams should monitor EFSA approvals for novel enzymes, as these often pave the way for UK market acceptance. This provides competitive advantage through novel ingredients that can reduce production costs and improve consumer appeal in functional food and beverage categories.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.